High Immunogenicity to Influenza Vaccination in Crohn's Disease Patients Treated with Ustekinumab.

Vaccines (Basel) · 2020 · PMC7565576 · PMID 32824111

Europe PMC DOI

hedged sentences

0.0560

closest p · 1.1× alpha

0.0640

boldest claim

The sentences

borderline significancep = 0.056so close (0.05 < p ≤ 0.1)

In the adalimumab group, seroprotection rates were lower three months post-vaccination compared to the other two groups, reaching borderline significance (81.8%, p = 0.056).

also in 7,017 other papers

borderline significantp = 0.064so close (0.05 < p ≤ 0.1)

Seroconversion Rates Seroconversion rates to the H3N2 strain were significantly different in the three groups at three months post-vaccination (T3: p = 0.014, Table 3 ) and borderline significant at one-month post-vaccination (T1: p = 0.064).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.